|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Current status of high on-treatment platelet reactivity in patients with coronary or peripheral arterial disease:Mechanisms,evaluation and clinical implications显示文摘Antiplatelet therapy with aspirin or clopidogrel or both is the standard care for patients with proven coronary or peripheral arterial disease,especially those undergoing endovascular revascularization procedures. However,despite the administration of the antiplatelet regiments,some patients still experience recurrent cardiovascular ischemic events. So far,it is well documented by several studies that in vitro response of platelets may be extremely variable. Poor antiplatelet effect of clopidogrel or high on-treatment platelet reactivity(HTPR) is under investigation by numerous recent studies. This review article focuses on methods used for the ex vivo evaluation of HTPR,as well as on the possible underlying mechanisms and the clinical consequences of this entity. Alternative therapeutic options and future directions are also addressed. | Stavros Spiliopoulos Georgios Pastromas | 2015 | World Journal of Cardiology2015，7，12： | 13 |
| 2 | Flecainide: Current status and perspectives in arrhythmia management显示文摘Flecainide acetate is a class IC antiarrhythmic agent and its clinical efficacy has been confirmed by the results of several clinical trials. Nowadays, flecainide is recommended as one of the first line therapies for pharmacological conversion as well as maintenance of sinus rhythm in patients with atrial fibrillation and/or supraventricular tachycardias. Based on the Cardiac Arrhythmia Suppression Trial study results, flecainide is not recommended in patients with structural heart disease due to high proarrhythmic risk. Recent data support the role of flecainide in preventing ventricular tachyarrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia associated both with ryanodine receptor and calsequestrin mutations. We herein review the current clinical data related to flecainide use in clinical practice and some concerns about its role in the management of patients with coronary artery disease. | George K Andrikopoulos Sokratis Pastromas Stylianos Tzeis | 2015 | World Journal of Cardiology2015，7，2： | 8 |
| 3 | Prevalence of Nonresponsiveness to Aspirin in Patients with Symptomatic Peripheral Arterial Disease Using True Point of Care Testing显示文摘 | Dimitrios Karnabatidis Stavros Spiliopoulos Georgios Pastromas Panagiotis Kitrou Nikolaos Christeas Konstantinos Katsanos Dimitrios Siablis | 2014 | CardioVascular and Interventional Radiology2014，，： | 1 |
| 4 | First reportof tirofiban-induced anemia (found in combination with severethrombocytopenia) 显示文摘 | Sakellariou D Pastromas S Koulouris S | 2009 | Tex Heart Inst J2009，36，1： | 1 |
| 5 | Clopidogrel Responsiveness in Patients Undergoing Peripheral Angioplasty显示文摘 | Georgios Pastromas Stavros Spiliopoulos Konstantinos Katsanos Athanasios Diamantopoulos Panagiotis Kitrou Dimitrios Karnabatidis Dimitrios Siablis | 2013 | CardioVascular and Interventional Radiology2013，，： | 1 |
| 6 | Platelet REsponsiveness to CLOpidogrel treatment after Peripheral endovascular procedures - The PRECLOP study: Clinical Impact and Optimal Cut-off Value of High On Treatment Platelet Reactivity显示文摘 | Stavros Spiliopoulos Georgios Pastromas Konstantinos Katsanos Panagiotis Kitrou Dimitrios Karnabatidis Dimitrios Siablis | 2013 | Journal of the American College of Cardiology2013，，： | 1 |
| 7 | Initial Experience With Ticagrelor in Patients With Critical Limb Ischemia and High On-Clopidogrel Platelet Reactivity Undergoing Complex Peripheral Endovascular Procedures显示文摘 | Stavros Spiliopoulos Konstantinos Katsanos Georgios Pastromas Athanasios Diamantopoulos Panagiotis Kitrou Dimitris Siablis Dimitris Karnabatidis | 2014 | CardioVascular and Interventional Radiology2014，，： | 1 |
| 8 | Combination of intravenous pulses of cyclophosphamide and methyprednizolone in patients with systemic sclerosis and interstitial lung disease显示文摘 | Yiannopoulos G Pastromas V Antonopoulis I | 2007 | Rheumatol Int2007，27，35： | 1 |
| 9 | Cardiac resynchronization therapy: Dire need for targeted left ventricular lead placement and optimal device programming显示文摘Cardiac resynchronization therapy(CRT) effected via biventricular pacing has been established as prime therapy for heart failure patients of New York Heart Association functional class Ⅱ, Ⅲ and ambulatory Ⅳ, reduced left ventricular(LV) function, and a widened QRS complex. CRT has been shown to improve symptoms, LV function, hospitalization rates, and survival. In order to maximize the benefit from CRT and reduce the number of non-responders, consideration should be given to target the optimal site for LV lead implantation away from myocardial scar and close to the latest LV site activation; and also to appropriately program the device paying particular attention to optimal atrioventricular and interventricular intervals. We herein review current data related to both optimal LV lead placement and device programming and their effects on CRT clinical outcomes. | Sokratis Pastromas Antonis S Manolis | 2014 | World Journal of Cardiology2014，6，12： | 1 |
| 10 | First report of tiroifban-induced anemia ( found in combination with severe thrombocytopenia) 显示文摘 | SAKELLARIOU D PASTROMAS S KOULOURIS S | 2009 | Tex Heart Inst J2009，36，1： | 1 |
| 11 | First Report of Tirofiban-Induced Anemia(Found in Combination with Severe Thrombocytopenia)显示文摘 | Sakellariou D Pastromas S Koulouris S | 2009 | Tex Heart Inst J2009，36，1： | 1 |
| 12 | First Report of TirofiBan- Induced Anemia (Found in Combination with Severe Thrombocytopenia) 显示文摘 | Sakellariou D Pastromas S Koulouris S | 2009 | Tex Heart Inst2009，36，1： | 1 |
| 13 | First reportof tirofiban-induced anemia (found in combination with severethrombocytopenia) 显示文摘 | Sakellariou D Pastromas S Koulouris S | 2009 | Tex Heart Inst J2009，36，1： | 1 |
| 14 | Inadequate heart rate control is associated with worse quality of life in patients with coronary artery disease and chronic obstructive pulmonary disease 显示文摘 | Andrikopoulos G Pastromas S Kartalis A | 2012 | Hellenlc J Cardiol2012，53，2： | 1 |
| 15 | Combination of intravenous pulses of cyclophosphamide and methylprednizolone in patients with systemic sclerosis and interstitial lung disease 显示文摘 | Yiannopoulos G Pastromas V Antonopoulos I | 2007 | Rheumatology international2007，27，4： | 1 |
| 16 | First report of tirofiban-induced anemia (found in combination with severe thrombocytopenia)显示文摘 | Sakellariou D Pastromas S Koulouris S | 2009 | Tex Heart Inst J2009，36，： | 1 |
| 17 | Postprandial lipemia:An under-recognized atherogenic factor in patients with diabetes mellitus显示文摘 | Pastromas S Terzi AB Tousoulis D | 2008 | International Journal of Cardiology2008，126，1： | 1 |
| 18 | Postprandial lipemia : An under-recognized atherogenie factor in patients with diabetes mellitus 显示文摘 | PASTROMAS S TERZI A B TOUSOULIS D | 2008 | Int J Cardiol2008，126，1： | 1 |
| 19 | Seasonal variation in fasting glucose and HbA1c in patients with type 2 diabetes显示文摘 | Gikas A Sotiropoulos A Pastromas V | 2009 | Prim Care Diabetes2009，3，2： | 1 |
| 20 | Postpran- dial lipemia: an under-recognized atherogenic factor in patients with diabetes mellitus显示文摘 | Pastromas S Terzi AB Tousoulis D | 2008 | Int J Cardiol2008，126，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员